Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAUDIA Trial
2023-509452-34-00Phase 2Completed
- Sponsor
- VivaCell Biotechnology
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etrinabdione in arteriosclerosis obliterans and type 2 diabetes mellitus (T2DM), sponsored by VivaCell Biotechnology. Primary endpoint: Incidence and severity of treatment-emergent adverse events (TEAEs). Started May 2024; status: completed.
02
Drugs
etrinabdione
03
Conditions
arteriosclerosis obliteranstype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-509452-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509452-34-00.